The subject of journal encompasses a wide range of important elements. Current Issue | New England Journal of Medicine. Explore the current issue of The New England Journal of Medicine (Vol. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. It's important to note that, tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer ...
Furthermore, the New England Journal of Medicine | Research & Review Articles on .... The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ... Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP... Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated ....
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ... Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. We conducted an ascending-dose phase 1 trial to assess the safety and efficacy of CTX310, a lipid-nanoparticle–encapsulated clustered regularly interspaced short palindromic repeats–Cas9 ...
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or progressed during or after ... Structured Exercise after Adjuvant Chemotherapy for Colon Cancer.
In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program ... Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day 1 and ... Equally important, encorafenib, Cetuximab, and mFOLFOX6 in - The New England Journal of ....
First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer ...
📝 Summary
Learning about journal is crucial for people seeking to this area. The insights shared in this article functions as a solid foundation for deeper understanding.